Activity of the Cancer Metabolism Inhibitor MPC-9528 in Xenograft Models: Comparison of Different Dosing Schedules.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2011.29.15_suppl.10529
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

P450 Inhibitor Ketoconazole Increased the Intratumor Drug Levels and Antitumor Activity of Fenretinide in Human Neuroblastoma Xenograft Models

International Journal of Cancer
Cancer ResearchOncology
2017English

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2014English

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors

Clinical Cancer Research
Cancer ResearchOncology
2018English

Synergistic Activity of the mTOR Inhibitor Ridaforolimus and the Antiandrogen Bicalutamide in Prostate Cancer Models

International Journal of Oncology
Cancer ResearchOncology
2012English

Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer According to Tumorigenicity in Patient-Derived Xenograft Models

Cancer Research and Treatment
Cancer ResearchOncology
2018English

Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Phase 2 Multicentre Trial Investigating Intermittent and Continuous Dosing Schedules of the Poly(ADP-Ribose) Polymerase Inhibitor Rucaparib in Germline BRCA Mutation Carriers With Advanced Ovarian and Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2016English

GSK1070916, a Potent Aurora B/C Kinase Inhibitor With Broad Antitumor Activity in Tissue Culture Cells and Human Tumor Xenograft Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy